Healthcare
•3734 stocks
•
Total Market Cap: Loading...
Price Performance Heatmap
5Y Price (Market Cap Weighted)
All Stocks (3734)
| Company | Market Cap | Price |
|---|---|---|
|
SLRN
Acelyrin, Inc.
Lonigutamab is pursued within immune-mediated/immunology therapeutic space (TED), fitting Immunology Therapeutics.
|
$228.61M |
$2.27
|
|
MPAA
Motorcar Parts of America, Inc.
MPAA markets and sells diagnostic equipment, such as the JBT-1 Bench Top tester.
|
$228.05M |
$11.68
+4.01%
|
|
CYDY
CytoDyn Inc.
Leronlimab is a monoclonal antibody therapeutic, aligning CytoDyn with Monoclonal Antibody Therapeutics.
|
$227.99M |
$0.37
|
|
NVCT
Nuvectis Pharma, Inc.
Nuvectis' lead asset NXP900 is a cancer-targeting therapy (SRC/YES1 kinase inhibitor), placing the company in Biotech - Oncology.
|
$227.97M |
$8.86
+6.11%
|
|
MDWD
MediWound Ltd.
MediWound's core products are enzymatic proteins/enzymes (NexoBrid, EscharEx) used for wound debridement, aligning with Recombinant Proteins & Enzymes.
|
$227.20M |
$17.71
+3.57%
|
|
IPSC
Century Therapeutics, Inc.
Directly develops iPSC-derived cell therapies (CAR-iT, CAR-iNK, Allo-Evasion-enabled products) and related platforms.
|
$227.00M |
$2.59
+6.15%
|
|
OSUR
OraSure Technologies, Inc.
OraSure's core offerings include diagnostic equipment such as OraQuick rapid tests and molecular diagnostics platforms.
|
$226.68M |
$3.17
-1.40%
|
|
QNCX
Quince Therapeutics, Inc.
Quince's AIDE platform is a drug-delivery platform encapsulating drugs in autologous red blood cells.
|
$226.67M |
$4.28
-2.73%
|
|
UTMD
Utah Medical Products, Inc.
Filshie Clip System is a surgical device used in gynecologic procedures, directly aligning with UTMD's Filshie Clip product line.
|
$226.34M |
$71.03
+2.13%
|
|
RNA
Atrium Therapeutics, Inc.
Direct product modality: oligonucleotide therapeutics (AOC platform) delivering RNA payloads.
|
$223.57M |
$14.40
+2.64%
|
|
CNTX
Context Therapeutics Inc.
The company's pipeline centers on T cell engaging bispecific antibodies (CTIM-76, CT-95, CT-202).
|
$223.27M |
$2.44
+6.77%
|
|
BNR
Burning Rock Biotech Limited
Burning Rock's brPROPHET MRD and MCED products are ctDNA-based diagnostics delivered as a liquid biopsy test.
|
$222.70M |
$21.02
-6.56%
|
|
MGNX
MacroGenics, Inc.
Company develops bispecific antibody therapies via its DART platform, including lorigerlimab.
|
$218.87M |
$3.45
+1.17%
|
|
ELMD
Electromed, Inc.
Electromed manufactures the SmartVest Clearway airway clearance medical device, fitting the Medical Devices & Biometrics investable theme.
|
$217.35M |
$25.97
+2.28%
|
|
SGHT
Sight Sciences, Inc.
Directly manufactures ophthalmic surgical devices (OMNI Surgical System, TearCare-related tools) used in eye care, i.e., ophthalmology devices.
|
$216.25M |
$4.09
+6.79%
|
|
INFU
InfuSystem Holdings, Inc.
InfuSystem directly provides infusion pumps and related medical device equipment, plus lifecycle management services.
|
$215.16M |
$10.59
+3.52%
|
|
PRQR
ProQR Therapeutics N.V.
ProQR's Axiomer platform uses oligonucleotide-based RNA editing (EONs) to direct ADAR-mediated editing.
|
$214.34M |
$2.00
+2.31%
|
|
CAMP
CAMP4 Therapeutics Corporation
Direct product category: oligonucleotide therapeutics (RNA Actuating Platform) using ASOs to upregulate gene expression.
|
$210.50M |
$4.50
-0.11%
|
|
SGMT
Sagimet Biosciences Inc.
Sagimet's lead and second FASN inhibitors (denifanstat, TVB-3567) are oral small-molecule therapeutics, directly aligning with this tag.
|
$210.41M |
$6.47
+4.60%
|
|
FENC
Fennec Pharmaceuticals Inc.
Direct product in oncology/supportive care with FDA-approved PEDMARK therapy for cisplatin-induced ototoxicity.
|
$210.13M |
$7.74
+2.45%
|
|
TARA
Protara Therapeutics, Inc.
TARA-2.00 is a cell therapy platform, representing the company’s lead product modality.
|
$209.91M |
$5.44
+6.04%
|
|
CPMV
Mosaic ImmunoEngineering Inc.
Lead oncology candidate MIE-101 defines CPMV's core product focus in cancer therapy.
|
$208.72M |
$0.52
|
|
CRGX
CARGO Therapeutics, Inc. Common Stock
CRGX's core offerings are oncology CAR-T therapies (firi-cel, CRG-23), placing it in Biotech - Oncology.
|
$206.13M |
$4.47
|
|
SLGL
Sol-Gel Technologies Ltd.
Proprietary microencapsulation drug-delivery platform is a core technology Sol-Gel uses to formulate topical therapies.
|
$205.79M |
$74.82
-0.66%
|
|
CRBU
Caribou Biosciences, Inc.
Company is developing gene-editing gene therapy platforms (CRISPR-based chRDNA) for therapeutic applications.
|
$205.63M |
$2.21
+2.56%
|
|
LFCR
Lifecore Biomedical, Inc.
Lifecore is a pure-play CDMO focused on sterile injectable drug development and manufacturing.
|
$201.57M |
$5.39
+3.65%
|
|
PROF
Profound Medical Corp.
Profound's flagship TULSA-PRO is a surgical device used for MR-guided prostate tissue ablation.
|
$200.79M |
$6.65
+0.45%
|
|
KRMD
KORU Medical Systems, Inc.
KRMD's core business is medical devices focused on patient-centric subcutaneous infusion systems (Freedom) and related components.
|
$200.58M |
$4.33
+3.47%
|
|
RELL
Richardson Electronics, Ltd.
Medical devices and equipment manufacturing including CT X-ray tubes and related products remain part of the portfolio.
|
$198.17M |
$13.64
+3.84%
|
|
LFMD
LifeMD, Inc.
LifeMD operates as a healthcare services provider with a multi-state medical group and in-house pharmacy; core service delivery.
|
$196.88M |
$4.09
+3.81%
|
|
ADAG
Adagene Inc.
Immunology Therapeutics as a broader modality applicable to immune-oncology.
|
$195.03M |
$3.79
-8.57%
|
Showing page 22 of 38 (3734 total stocks)
Loading company comparison...
Loading industry trends...
Loading research report...
